Clinical Trials Logo

Clinical Trial Summary

The postprandial dumping syndrome is a frequent consequence of Roux-en-Y Gastric ByPass due to the rapid emptying of the stomach remnant in to the intestinal lumen. Dumping-related symptoms occur very early after eating (within 30 minutes), are not associated with concurrent hypoglycemia, and are most prominent in the early postoperative period. This syndrome very debilitating for the patient can be improved by dietary and nutritional recommendations. We hypothesize that a personalized approach based on dietary and nutritional recommendations conducted by a nurse would likely to decrease the frequency of dumping syndrome and improve the postoperative quality of life of patients in the early postoperative period.


Clinical Trial Description

The Roux-en-Y Gastric ByPass is considered the gold standard of weight loss surgery and is the most commonly performed bariatric procedure worldwide.The postprandial dumping syndrome is a frequent consequence of gastrojejunal anastomosis due to the rapid emptying of the stomach remnant in to the intestinal lumen. Dumping-related symptoms occur very early after eating (within 30 minutes), are not associated with concurrent hypoglycemia, and are most prominent in the early postoperative period. The symptoms of dumping syndrome include nausea, abdominal cramps, diarrhea, dizzy spells, weakness and cold sweats either with or after eating.This syndrome very debilitating for the patient can be improved by dietary and nutritional recommendations. We hypothesize that an individualized approach based on dietary and nutritional recommendations and monitoring of patients conducted by a nurse in the first three months after surgery would likely to decrease these problems and improve the postoperative quality of life of patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02891330
Study type Interventional
Source University Hospital, Lille
Contact
Status Completed
Phase N/A
Start date March 2, 2017
Completion date December 18, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05759689 - Fat Supplementation on Dumping Syndrome Related Symptoms After Gastric Surgery N/A
Recruiting NCT04028193 - Fat Supplementation on Dumping Syndrome Associated Symptoms N/A
Recruiting NCT00543179 - Treatment of the Dumping Syndrome With Lanreotide Autogel® Phase 4
Not yet recruiting NCT04522193 - Dumping Syndrome and Esophageal Atresia N/A
Completed NCT02525705 - Dumping Syndrome After Operation of Esophageal Atresia Type III N/A
Completed NCT01794793 - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Phase 4
Completed NCT03734627 - Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery
Terminated NCT02836353 - Metabolic Consequences of Gastrointestinal Surgery N/A
Completed NCT05057819 - Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass Phase 4
Completed NCT02971631 - Gastrectomy, Eating Behaviour and GLP-1 N/A
Completed NCT01923649 - SOMATULINE Autogel 90 mg IN DUMPING SYNDROME Phase 2